Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tailored smoking cessation for cancer patients shows promise

NCT ID NCT07166120

Symptom relief Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study tests whether a personalized approach to smoking cessation helps cancer patients quit. Researchers will use patients' clinical, genetic, and biomarker information to create tailored treatment plans. The study involves 112 participants and compares this precision treatment to usual care, measuring quit rates and medication use at 6 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
behavioral intervention with personalized risk feedback and treatment recommendations
What this could lead to
If successful, this could provide a more effective way to help cancer patients quit smoking, potentially improving their survival and quality of life.
What could go wrong
This is a small early-stage feasibility study, so results may not be conclusive. The personalized approach may not work better than standard care, and quitting smoking is difficult even with support.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 132 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Eligibility Criteria for Clinicians: * Clinician from participating oncology/hematology clinic * At least 18 years of age * Can speak and understand English Inclusion Criteria for Patients: * Patient at participating clinic * Age 18-89 years * Current smoking (average cigarettes per day ≥5) * Can speak and understand English * Willing to consider medication to help reduce craving or smoking such as nicotine patch, lozenge, or varenicline Exclusion Criteria for Patients: * Active use of smoking cessation medication (within the past 30 days) * Receipt of smoking cessation medication or prescription for smoking cessation medication (within the past 30 days) * Having a contradiction for cNRT or varenicline (allergic reactions, current cardiac problems, pregnancy) * Patients who were deemed by the investigator to be ineligible for participation in the trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Physician's role are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

nicotine dependence Smoking Smoking Cessation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Physician's role Smoking Smoking cessation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • John Cochran Veteran's Affairs Medical Center

    RECRUITING

    St Louis, Missouri, 63106, United States

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.